Joint Program Executive Office Chemical and Biological Defense

GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins

Retrieved on: 
Thursday, October 19, 2023
IND, Therapy, Biotechnology, Head, Protein engineering, DOD, Antibody, Partnership, Joint Program Executive Office Chemical and Biological Defense, Radiation, Infection, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, Army Contracting Command, SAN, Vaccine, Chemical substance, Grifols

The modification, awarded through Army Contracting Command, will expand the value of the agreement to $11.8M.

Key Points: 
  • The modification, awarded through Army Contracting Command, will expand the value of the agreement to $11.8M.
  • Using high-throughput, single-cell genomic and protein engineering technology GigaGen will create cell lines that express recombinant human antibodies against BoNT A and B.
  • The polyclonal cell bank can then be used to continuously manufacture the BoNT A & B hyperimmune product at existing manufacturing facilities.
  • This effort will demonstrate an accelerated, target-specific therapeutic manufacturing platform’s ability to rapidly create and express polyclonal antibody cell banks against BoNT A and B.

Humanetics Corporation Awarded Contract From Department of Defense to Develop First FDA Approved Drug to Prevent Radiation Injury

Retrieved on: 
Wednesday, September 6, 2023
Defense, Other Science, Radiology, White House, Federal Government, Pharmaceutical, Research, Other Defense, Oncology, Contracts, Homeland Security, Science, Clinical Trials, Public Policy, Government, FDA, Biotechnology, Health, Law Enforcement, Emergency Services, COVID-19, Military, BIO, Radiation, Acute radiation syndrome, Therapy, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, ARS, United States Department of Defense, OTA, Policy, Clinical trial, Cancer, Lung cancer, Food and Drug Administration, Terrorism, Bangladesh Technical Education Board, DOD, JPM, Humanetics, Patient, Joint Program Executive Office Chemical and Biological Defense, Chronic radiation syndrome, Conventional weapon, Radiation exposure, Food, Pharmaceutical industry, Vaccine, Chemical substance

Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.

Key Points: 
  • Humanetics Corporation (Humanetics) announced today that it was awarded a 5-year contract from the Department of Defense (DOD) to develop its drug, BIO 300, as a medical countermeasure to prevent bodily harm caused by acute exposure to radiation.
  • In addition, the OTA agreement provides options for the DOD to fund all activities required to bring BIO 300 to full FDA approval.
  • Exposure to radiation from accidental or intentional sources can lead to acute radiation syndrome (ARS), which consists of numerous serious and life-threatening injuries.
  • The JPEO-CBRND will manage the OTA agreement, overseeing the development of BIO 300, exclusively licensed to Humanetics for advanced development and FDA licensing.

A-Alpha Bio Raises $22.4M in Series A2 to Scale Protein-Protein Interaction Data Platforms and Accelerate Internal Pipeline Development

Retrieved on: 
Tuesday, July 25, 2023
DNA, Gilead Sciences, Genetic engineering, Therapy, HIV, Serie A2 (basketball), National Science Foundation, Lawrence Livermore National Laboratory, ML, Bristol Myers Squibb, Medicine, Swiss National Science Foundation, Machine learning, Joint Program Executive Office Chemical and Biological Defense, Engineering, Alpha-enolase, Bill, Health, Bill & Melinda Gates Foundation, Synthetic biology, Radiation, Pharmaceutical industry, Chemical substance

SEATTLE, July 25, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning (ML) company that measures and engineers protein-protein interactions, today announced a $22.4M Series A2. The round was led by previous investor Perceptive Xontogeny Ventures, with strong support from Madrona and other existing investors. Breakout Ventures joined the round as a new investor, and Lindy Fishburne, Managing Partner at Breakout Ventures, will join the board as an observer.

Key Points: 
  • The round was led by previous investor Perceptive Xontogeny Ventures, with strong support from Madrona and other existing investors.
  • The funding will enable further development of the company's AlphaSeq and AlphaBind platforms and accelerate their oncology-focused internal pipeline.
  • These collaborations underscore the flexibility of A-Alpha's platforms to address a broad range of complex biological challenges, contributing to the development of next-generation therapeutics.
  • Innovating at the intersection of wet lab and computation, A-Alpha Bio is leveraging their synthetic biology and ML platforms, AlphaSeq and AlphaBind.

U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure

Retrieved on: 
Tuesday, July 18, 2023
CBDP, Joint Program Executive Office Chemical and Biological Defense, CBRN, U.S. Department of Defense Strategy for Operating in Cyberspace, Army, RAD, Slave & Otis, United States Joint Forces Command, Naloxone, ROCS, Military personnel, DOD, JPM, Acquisition, The Reconstruction (1970 film), Atropine, Poisoning, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nerve, Food, Medical imaging, Risk management, Chemical substance, Radiation

The reconstitution development contract is valued at more than $39 million over the next five years.

Key Points: 
  • The reconstitution development contract is valued at more than $39 million over the next five years.
  • Atropine sulfate injection is used for the treatment of poisoning by susceptible organophosphorus nerve agents having cholinesterase activity as well as organophosphorus or carbamate insecticides.
  • The DOD intends the RAD-A to be an important addition to the auto-injector products that constitute a layered defense against CBRN threats for military personnel and potentially civilian stockpiles.
  • The JPM CBRN Medical facilitates the advanced development and acquisition of medical countermeasures and systems to enhance the Nation’s CBRN response capability.

Draper Equips Small UAVs for Tomorrow's Battlefield - news

Retrieved on: 
Monday, July 10, 2023
Human, GPS, Radiation, CBRN, Atmosphere, TAK, Tree, Unmanned aerial vehicle, Sensor, Lidar, Government, Robotics, Suave House Records, Joint Program Executive Office Chemical and Biological Defense, Map, Algorithm, U.S. Department of Defense Strategy for Operating in Cyberspace, Draper, UAV, Environment, Software, Instrumentation, Surveying, Satellite navigation device

CAMBRIDGE, Mass., July 10, 2023 /PRNewswire-PRWeb/ -- Battlefields entered a new era with the introduction of small unmanned aerial vehicles, or sUAVs. Commonly called drones, sUAVs enable soldiers to gain an aerial view of the battlefield and improve their situational awareness of the battlespace.

Key Points: 
  • CAMBRIDGE, Mass., July 10, 2023 /PRNewswire-PRWeb/ -- Battlefields entered a new era with the introduction of small unmanned aerial vehicles, or sUAVs.
  • Commonly called drones, sUAVs enable soldiers to gain an aerial view of the battlefield and improve their situational awareness of the battlespace.
  • It's a situation that's challenging the developer community, according to Won Kim, a program manager at Draper .
  • In addition to working with autonomous systems, Draper has assisted U.S. government agencies with projects including cybersecurity, technology protection and miniature cryptography for high stress environments.

EQS-News: Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program

Retrieved on: 
Wednesday, July 5, 2023
Linda, Immortalised cell line, ASPR, Office of Inspector General, U.S. Department of Health and Human Services, Plague, Medicine, Biomedical Advanced Research and Development Authority, Joint Program Executive Office Chemical and Biological Defense, U.S. Department of Defense Strategy for Operating in Cyberspace, Just, HHS, United States Department of Defense, OTA, AND, JUST, De novo, Orthopoxvirus, Administration, DOD, Development, MCDC, Administration for Strategic Preparedness and Response, Mab, ISIN, Frankfurt Stock Exchange, BARDA, Radiation, EVO, MDAX, Vaccine, Fine chemical, Pharmaceutical industry, Defense, Hook effect, Chemical substance

Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program

Key Points: 
  • Just – Evotec Biologics awarded second contract from U.S. Department of Defense under accelerated antibodies program
    The issuer is solely responsible for the content of this announcement.
  • Under the contract, Just – Evotec Biologics will develop drug product prototype(s) from discovery through the execution of Phase I first-in human (“FIH”) clinical trials.
  • Dr Linda Zuckerman, Executive Vice President Global Head Biotherapeutics at Just – Evotec Biologics commented: “It is an honor to expand our collaboration with the DOD’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (“JPEO-CBRND”) with this second target program effort to support the DOD’s Accelerated Antibodies Program.
  • A first contract under the Accelerated Antibodies Program for the development of mAbs against plague was awarded to Just – Evotec Biologics in September of 2022.

A-Alpha Bio and Lawrence Livermore National Laboratory expand collaboration to accelerate antibody discovery and development for biothreats

Retrieved on: 
Tuesday, May 16, 2023
Antigen, Coronavirus, Immunoglobulin heavy constant alpha 1, Lawrence Livermore National Laboratory, ML, Research, COVID, Antibody, DOD, Machine learning, Joint Program Executive Office Chemical and Biological Defense, LLNL, Drug discovery, PPI, Synthetic biology, Radiation, Vaccine, Chemical substance

SEATTLE, May 16, 2023 /PRNewswire-PRWeb/ -- A-Alpha Bio, a synthetic biology and machine learning company that measures and engineers protein-protein interactions, and Lawrence Livermore National Laboratory (LLNL), a federally funded research and development center, today announced their intention to collaborate to combat multiple pathogen families of concern. To enable this work, A-Alpha Bio has been awarded an additional $2.4M sub-contract from the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in support of the Generative Unconstrained Intelligent Drug Engineering (GUIDE) Program, which the company will use to generate large-scale and quantitative protein-protein interaction (PPI) data and support LLNL's advanced high-performance computational models for antibody discovery and development.

Key Points: 
  • The experimental data has proven valuable for building and refining LLNL's computational models for predicting antibody sequences that bind to current and possible future variants of concern.
  • Beyond the pandemic, there is a well-recognized need to ensure preparation for other potential biological threats.
  • These data are particularly valuable for training and validating ML models aimed at predicting desirable antibody sequences for therapeutic development.
  • "Our collaboration with the A-Alpha Bio team leverages their platform and expertise toward state-of-the-art computational models that will accelerate drug discovery."

U.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 million

Retrieved on: 
Thursday, February 23, 2023
Department of Defence, American Epilepsy Society, AAS, Injection, U.S. Department of Defense Strategy for Operating in Cyberspace, Status epilepticus, Radiation, CANA, DOD, FDA, Laboratory, U.S. Defense Department firefighters, Nation, Joint Program Executive Office Chemical and Biological Defense, Food and Drug Administration, Defense, United States Joint Forces Command, Thigh, CBRN, Food, Seizure, Slave & Otis, Pharmaceutical industry, Midazolam, Chemical substance, Rafa

JERUSALEM, Feb. 23, 2023 /PRNewswire/ -- Rafa Laboratories LTD. ("Rafa") was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Under this follow-on production agreement, Rafa has manufactured and began delivering 10mg Midazolam Injection autoinjectors to the Joint Force since December 2022.

Key Points: 
  • This first in market product was developed by Rafa in cooperation with the U.S. Department of Defense
    JERUSALEM, Feb. 23, 2023 /PRNewswire/ -- Rafa Laboratories LTD. ("Rafa") was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
  • Under this follow-on production agreement, Rafa has manufactured and began delivering 10mg Midazolam Injection autoinjectors to the Joint Force since December 2022.
  • As such, this new Advanced Anticonvulsant System (AAS) autoinjector can be used to treat seizures resulting from nerve agent exposure.
  • This production agreement demonstrates further cooperation between Rafa and the JPEO-CBRND, having previously collaborated on the production of Rafa's Atropine autoinjector that was launched in the U.S. in 2017.

U.S. Department of Defense Awards Rafa Laboratories Production FOLLOW-ON Agreement of over $45 million

Retrieved on: 
Thursday, February 23, 2023
Department of Defence, American Epilepsy Society, AAS, Injection, U.S. Department of Defense Strategy for Operating in Cyberspace, Status epilepticus, Radiation, CANA, DOD, FDA, Laboratory, U.S. Defense Department firefighters, Nation, Joint Program Executive Office Chemical and Biological Defense, Food and Drug Administration, Defense, United States Joint Forces Command, Thigh, CBRN, Food, Seizure, Slave & Otis, Pharmaceutical industry, Midazolam, Chemical substance, Rafa

JERUSALEM, Feb. 23, 2023 /PRNewswire/ -- Rafa Laboratories LTD. ("Rafa") was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND). Under this follow-on production agreement, Rafa has manufactured and began delivering 10mg Midazolam Injection autoinjectors to the Joint Force since December 2022.

Key Points: 
  • This first in market product was developed by Rafa in cooperation with the U.S. Department of Defense
    JERUSALEM, Feb. 23, 2023 /PRNewswire/ -- Rafa Laboratories LTD. ("Rafa") was awarded a follow-on production agreement for a total value of over $45 million (W911SR2390004) from the Defense Department's (DOD) Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND).
  • Under this follow-on production agreement, Rafa has manufactured and began delivering 10mg Midazolam Injection autoinjectors to the Joint Force since December 2022.
  • As such, this new Advanced Anticonvulsant System (AAS) autoinjector can be used to treat seizures resulting from nerve agent exposure.
  • This production agreement demonstrates further cooperation between Rafa and the JPEO-CBRND, having previously collaborated on the production of Rafa's Atropine autoinjector that was launched in the U.S. in 2017.

The Access to Advanced Health Institute Announces $3M Award to Develop an Intranasal Pan-Viral Countermeasure against Respiratory Viruses

Retrieved on: 
Wednesday, February 15, 2023
Research, General Health, Contracts, Pharmaceutical, Infectious Diseases, Defense, Clinical Trials, Science, COVID-19, Other Science, Health, Military, Unitary state, Defense Innovation Unit, DIU, OTA, Urinary tract infection, Acceleration, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Hospital, Human, United States Department of Defense, Virus, TLR, Parasitism, Immunity, Infectious Disease Research Institute, Joint Program Executive Office Chemical and Biological Defense, Safety, JPM, Government, Patient, Access, SLA, Temperature, Nipah virus, TLR4, Immune system, Amoebiasis, Fungus, VAMP, Disease, Notifiable disease, Multimedia, Principal, Cancer, Vaccine, Chemical substance, Radiation

AAHI will be working with the DIU and JPM CBRN Medical to develop a prototype nasal spray using AAHI’s novel formulation of two adjuvants, substances that enhance immune responses.

Key Points: 
  • AAHI will be working with the DIU and JPM CBRN Medical to develop a prototype nasal spray using AAHI’s novel formulation of two adjuvants, substances that enhance immune responses.
  • AAHI’s adjuvant formulation platform enables development of temperature-stable products that can be easily distributed and stored to support the health and safety of warfighters.
  • AAHI will use its adjuvant formulation platform to develop a prototype product that promises to shorten timelines for emergency response to and mitigate impacts from biological threats.
  • AAHI’s collaboration with the DoD will build on AAHI’s over two decades of formulation expertise and broad portfolio of adjuvant formulations.